<DOC>
	<DOCNO>NCT00856492</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , paclitaxel albumin-stabilized nanoparticle formulation , doxorubicin , cyclophosphamide , work different way stop growth tumor cell , either kill cell stop divide . Colony-stimulating factor , pegfilgrastim , may increase number immune cell find bone marrow peripheral blood may help immune system recover side effect chemotherapy . Monoclonal antibody , bevacizumab , block tumor growth different way . Some find tumor cell kill carry tumor-killing substance . Others interfere ability tumor cell grow spread . Bevacizumab may also may stop growth tumor cell block blood flow tumor . Giving treatment surgery may make tumor small reduce amount normal tissue need remove . It yet know treatment regimen effective treat woman breast cancer . PURPOSE : This randomized phase II trial study paclitaxel albumin-stabilized nanoparticle formulation , doxorubicin , cyclophosphamide , pegfilgrastim compare well work give without bevacizumab treat woman inflammatory locally advanced breast cancer .</brief_summary>
	<brief_title>S0800 , Nab-Paclitaxel , Doxorubicin , Cyclophosphamide , Pegfilgrastim With Without Bevacizumab Treating Women With Inflammatory Locally Advanced Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - To compare pathologic complete response rate woman HER2/neu-negative inflammatory locally advanced breast cancer treat paclitaxel albumin-stabilized nanoparticle formulation , doxorubicin hydrochloride , cyclophosphamide , pegfilgrastim v without bevacizumab . - To compare overall survival patient treat regimen . - To assess whether correlation bevacizumab stratification factor ( type disease hormone receptor status ) . - To compare toxicity regimens . - To explore molecular biomarkers related biology outcome inflammatory breast cancer . - To explore potential molecular biomarkers predict response therapy drug sensitivity . - To evaluate biomarkers respect sequence paclitaxel albumin-stabilized nanoparticle formulation doxorubicin hydrochloride/cyclophosphamide/pegfilgrastim administration patient receive bevacizumab . - To explore residual cancer burden correlate outcome . - To evaluate time treatment failure prior surgery . - To evaluate disease-free survival time surgery patient undergo definitive surgery . OUTLINE : This multicenter study . Patients stratify accord type disease ( inflammatory v locally advance breast cancer ) hormone receptor status ( positive [ estrogen receptor ( ER ) + and/or progesterone receptor ( PgR ) + ] v negative [ ER- PgR- ] ) . Patients randomize 1 3 treatment arm . - Arm I : Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV 30 minute day 1 bevacizumab IV 30- 90-minutes day 1 week 1-12 . Patients receive doxorubicin hydrochloride IV cyclophosphamide IV day 1 pegfilgrastim SC day 2 week 14 , 16 , 18 , 20 , 22 , 24 . - Arm II : Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV 30 minute day 1 week 1-12 . Patients receive doxorubicin hydrochloride IV cyclophosphamide IV day 1 pegfilgrastim SC day 2 week 14 , 16 , 18 , 20 , 22 , 24 . - Arm III : Patients receive doxorubicin hydrochloride IV cyclophosphamide IV day 1 pegfilgrastim SC day 2 week 1 , 3 , 5 , 7 , 9 , 11 . Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV 30 minute day 1 week 14-25 . In arm , patient stable respond disease undergo surgery 3-6 week completion chemotherapy . Patients may undergo radiotherapy 5 day week 6 week . Serum , whole blood , tissue sample collect periodically biomarker analysis , circulate endothelial cell analysis , pharmacogenomic study , respectively . After completion study treatment , patient follow every 6 month 1 year annually 4 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically pathologically confirm breast cancer meet one follow criterion : Locally advanced disease ( stage IIIB disease , stage IIB/IIIA , stage IIIC disease ) Inflammatory disease meeting follow two clinicopathologic criterion : Diffuse erythema AND edema ( peau d'orange ) breast involve majority skin breast , i.e. , 50 % A biopsy demonstrate cancer either within dermal lymphatics OR breast parenchyma HER2/neunegative tumor demonstrate 0 1+ ( weak staining ) DAKO , IHC , equivalent test OR gene amplification FISH* 2+ DAKO IHC allow provide FISH* negative NOTE : *A negative FISH test ratio &lt; 1.8 FISH HER2 gene copy &lt; 4.0 ; positive negative result available FISH test , negative result acceptable study entry Hormone receptor status know PATIENT CHARACTERISTICS : Menopausal status specify Zubrod performance status 02 Granulocyte count &gt; 1,500/mm^3 ANC ≥ 1,500/mm^3 Platelet count &gt; 100,000/mm^3 Hemoglobin 9.0 g/dL Serum creatinine ≤ 1.5 time upper limit normal ( ULN ) Bilirubin ≤ 1.5 mg/dL ALT AST ≤ 3 time ULN Alkaline phosphatase ≤ 2.5 ULN ( unless bone metastasis present absence liver metastasis ) Urine protein : creatinine ratio ≤ 0.5 OR urine protein &lt; 1,000 mg 24hour urine collection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Able take oral medication ( e.g. , uncontrolled nausea , vomit , diarrhea , lack physical integrity upper gastrointestinal tract , malabsorption syndrome ) QTc &lt; 500 msec EKG LVEF normal MUGA ECHO ( patient hypertension patient &gt; 60 year age ) NYHA class II cardiac function baseline ECHO/MUGA ( patient receive central thoracic radiotherapy include heart radiotherapy port , patient history class II heart failure asymptomatic treatment eligible ) No history stroke ( cerebrovascular accident ) , transient ischemic attack , cardiac event within past 12 month , include follow : Myocardial infarction ( include severe/unstable angina ) Coronary/peripheral artery bypass graft Symptomatic congestive heart failure Pulmonary embolism No poorly control hypertension , define recurrent persistent ( ≥ 24 hour ) elevate blood pressure ( i.e. , systolic blood pressure ≥ 140 mm Hg and/or diastolic blood pressure ≥ 90 mm Hg ) No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer situ cervical cancer Peripheral neuropathy &lt; grade 2 PRIOR CONCURRENT THERAPY : No prior tyrosine kinase inhibitor More 5 year since prior chemotherapy , radiotherapy , biologic therapy ( e.g. , trastuzumab bevacizumab ) invasive breast cancer At least 7 day since prior hormonal therapy At least 7 day since prior concurrent strong CYP3A4 inhibitor ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconazole ) grapefruit juice No concurrent CYP3A4 inducer ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. John 's wort ) No concurrent therapy treatment breast cancer except bisphosphonates No concurrent brachytherapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>inflammatory breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>HER2-negative breast cancer</keyword>
	<keyword>estrogen receptor-negative breast cancer</keyword>
	<keyword>estrogen receptor-positive breast cancer</keyword>
	<keyword>progesterone receptor-negative breast cancer</keyword>
	<keyword>progesterone receptor-positive breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
</DOC>